AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Cytokinetics (CYTK)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

45.66

-0.50 (-1.08%)

At close: Feb 18, 2025, 3:59 PM

45.47

-0.43%

After-hours: Feb 18, 2025, 07:46 PM EST

undefined% (undefined)

Bid	45
Market Cap	5.39B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.38
PE Ratio (ttm)	-8.49
Forward PE	n/a
Analyst	Buy

Ask	48
Volume	1,291,731
Avg. Volume (20D)	1,378,035
Open	46.09
Previous Close	46.16
Day's Range	45.46 - 48.30
52-Week Range	40.53 - 81.36
Beta	undefined

About CYTK

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 30, 2004

Employees 423

Stock Exchange NASDAQ

Ticker Symbol CYTK

Website https://www.cytokinetics.com

Full Company Profile

Analyst Forecast

According to 17 analyst ratings, the average rating for CYTK stock is "Buy." The 12-month stock price forecast is $79, which is an increase of 73.00% from the latest price.

Buy 88.24%

Hold 11.76%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Cytokinetics is scheduled to release its earnings on Feb 27, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

5 days ago

+10.91%

Cytokinetics shares are trading higher amid rumors... Unlock content with Pro Subscription

2 months ago

+4.56%

Cytokinetics shares are trading higher after the company announced that Sanofi will acquire exclusive rights from Corxel Pharmaceuticals to develop and commercialize aficamten in Greater China for the treatment of hypertrophic cardiomyopathy.

News

3 weeks ago · zacks.com

CYTK Stock Rises as Enrollment Begins in Phase II Heart Failure Study

Cytokinetics stock up as the company initiates patient enrollment in its mid-stage study of pipeline candidate, CK-586, for treating heart failure patients.

4 weeks ago · benzinga.com

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Stifel initiated coverage on Cytokinetics Incorporated CYTK, noting the company's catalyst rich one to two years.

1 month ago · seekingalpha.com

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Cytokinetics is advancing aficamten, a potential competitor to Camzyos, targeting hypertrophic cardiomyopathy (HCM). Strategic licensing deals with Sanofi and Bayer secure resources and focus US comme...

2 months ago · fool.com

Why Cytokinetics Stock Was a Nearly 5% Winner Today

California-based biotech Cytokinetcs (CYTK 4.56%) finished the trading week in style, as its stock price outperformed many other titles by rising nearly 5% on Friday. News of a fresh licensing deal in...

2 months ago · zacks.com

Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report?

Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?

2 months ago · zacks.com

Cytokinetics Initiates Confirmatory Study on Heart Failure Drug

CYTK opens enrollment in the phase III COMET-HF study on omecamtiv mecarbil in patients with symptomatic heart failure with severely reduced ejection fraction.

2 months ago · zacks.com

FDA Accepts Cytokinetics' Application for Cardiovascular Drug

CYTK's NDA is seeking approval for the lead pipeline candidate, aficamten, which the FDA accepted and assigned a target action date of Sept. 26, 2025.

3 months ago · zacks.com

Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan

BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.

3 months ago · reuters.com

Bayer acquires rights to Cytokinetics' heart drug in Japan

Bayer on Tuesday struck a collaboration deal with U.S. biotech firm Cytokinetics to acquire certain rights in Japan to an experimental heart drug, as the German group strengthens its cardiovascular bu...